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Abstract
A key question in precision medicine is how functional heterogeneity in solid tumours informs therapeutic sensi-
tivity. We demonstrate that spatial characteristics of oncogenic signalling and therapy response can be modelled
in precision-cut slices from Kras-driven non-small-cell lung cancer with varying histopathologies. Unexpectedly,
profiling of in situ tumours demonstrated that signalling stratifies mostly according to histopathology, show-
ing enhanced AKT and SRC activity in adenosquamous carcinoma, and mitogen-activated protein kinase (MAPK)
activity in adenocarcinoma. In addition, high intertumour and intratumour variability was detected, particularly
of MAPK and mammalian target of rapamycin (mTOR) complex 1 activity. Using short-term treatment of slice
explants, we showed that cytotoxic responses to combination MAPK and phosphoinositide 3-kinase–mTOR inhi-
bition correlate with the spatially defined activities of both pathways. Thus, whereas genetic drivers determine
histopathology spectra, histopathology-associated and spatially variable signalling activities determine drug sen-
sitivity. Our study is in support of spatial aspects of signalling heterogeneity being considered in clinical diagnostic
settings, particularly to guide the selection of drug combinations.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Cancer biomedicine is experiencing a surge in the
approval of compounds that target driver mutations,
and targetable mutations are particularly prevalent in
non-small-cell lung cancer (NSCLC) [1]. However, sub-
stantial genomic and functional tumour heterogeneity
compromises treatment efficacy [2], and this includes
heterogeneity in oncogenic signalling activities [3].
Despite the availability of a range of molecules to target
signalling, remarkably little is known about the in situ
heterogeneity of signalling activities, and their context
dependence.
When the response to targeted drugs is studied ex
vivo, it is important for disease models to reflect the
tumour-intrinsic heterogeneity in oncogenic func-
tions, including signalling. Precision-cut tumour slices,
which capture the native tumour in its microenviron-
ment, constitute an attractive model with which to
address this need. Within the IMI-PREDECT project
(www.predect.eu), we developed a workflow for
short-term culture of tumour slices, and showed that
organotypic supports and atmospheric oxygen are strict
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requirements for tissue viability [4]. A number of other
studies have shown that responses to cytotoxic agents or
selected targeted compounds can be modelled in clinical
tumour-derived slices [5–11]. However, the question
remains of how the in situ spatial signalling hetero-
geneity affects the pharmacodynamics of signalling
inhibitors.
We set out to answer these questions by using two
widely studied murine NSCLC models, namely those
driven by the KrasG12D (Kras) oncogene, concomi-
tantly with loss of either the tumour suppressor gene
Trp53 (p53) [12] or the serine/threonine kinase 11
gene (Stk11, also known as Lkb1) [13–16]. These are
the most common drivers of clinical NSCLC, with
approximate gene alteration rates of 20% for LKB1,
36% for KRAS and 46% for TP53 in adenocarcino-
mas (ACs) [17,18]. Tumours are initiated from differ-
ent progenitors, using adenoviruses that predominantly
target Cre recombinase to either alveolar type II cells
expressing surfactant protein C (Ad5-SPC-Cre), or to
bronchiolar club cells expressing club cell antigen 10
(Ad5-CC10-Cre) [19,20]. Kras;p53 (KP) [21] tumours
initiated by either of these viruses lead to the forma-
tion of ACs and papillary ACs of varying grades [19].
In contrast, Kras;Lkb1 (KL) mice develop more aggres-
sive tumours with an expanded histopathology spectrum
[14,16], and we recently showed that histotype spectra
are dependent on the cell of origin: whereas alveolar
progenitors predominantly lead to the formation of pap-
illary AC, bronchiolar progenitors predominantly lead to
the formation of adenosquamous carcinoma (ASC) and
occasional mucinous or acinar AC [22]. Importantly, we
found that KL-driven papillary AC and ASC histotypes
show differences in immune-related gene signatures and
immune microenvironments [22].
To assess the impact of spatial signalling hetero-
geneity on therapeutic sensitivities, we first profiled
Kras-associated signalling activities, and proliferation
and viability markers, in KP and KL NSCLC lesions.
Our data show that, whereas genetic drivers define the
histopathology spectrum, tumour-specific signalling
mostly aligns with histopathology, but also shows high
intralesion and interlesion heterogeneity. Importantly,
cytotoxic drug responses to ex vivo treatment with
Kras-related signalling inhibitors correspond with
regional activities of the targeted pathways. Our study
thus emphasises the need, and informs on methods,
to consider the full complexity of spatial oncogenic
signalling in diagnostic assay design.
Materials and methods
Mice and tissue preparation
Animals, breeding and intranasal infections with
progenitor cell-directed Ad5-Cre viruses to initiate
tumour formation were performed as described pre-
viously [22]. Moribund mice were killed by cervical
dislocation, and tumour-bearing lungs were either
processed for tumour slice culture, or immediately fixed
with 4% formaldehyde overnight at ambient tempera-
ture. Precision-cut tumour slices were fixed with 4%
formaldehyde overnight at 4 ∘C. Fixed samples were
paraffin-embedded, and sections (4 μm) were processed
for haematoxylin and eosin (H&E) staining or immuno-
histochemical (IHC) analysis. Animal handling and
studies were performed according to guidelines from
the Finnish National Board of Animal Experimentation
(ESAVI/857/04.10.07/2013).
Human lung cancer specimens and tissue
microarrays (TMAs)
Surgically resected tumour specimens were received
from NSCLC patients, with informed consent, at the
Hospital District of Helsinki and Uusimaa (HUS), as
approved by the ethical board of the Joint Authority
for the HUS, Finland (Dnro: 85/13/03/00/15). Surgi-
cal specimens were dissected by a clinical patholo-
gist prior to slicing. For TMAs, archived formalin-fixed
paraffin-embedded tumour specimens were collected
from 66NSCLC patients operated on during 2000–2015
at the Hospital District of Helsinki. According to the
International Association for the Study of Lung Can-
cer/American Thoracic Society/European Respiratory
Society NSCLC classification system [23], 13 speci-
mens were diagnosed as ASC, 25 as papillary AC, and
28 as squamous cell carcinoma (SCC). TMAs were
prepared manually with 2-mm-diameter cores. Depend-
ing on tumour size, two or three replicate cores were
included, and both SCC and AC components of ASC
tumours were represented.
Tumour slicing, culture, and drug treatments
Murine NSCLC tumours and clinical specimens were
precision-cut to make 200-μm slices with a VT1200S
microtome (Leica Biosystems, Wetzlar, Germany), as
described previously [4]. Murine slices were trans-
ferred to rotating incubators (Alabama Research &
Development, Munford, AL, USA) (supplementary
material, Figure S2A), within 90–120min after mice
had been killed. Surgical specimens arrived for slicing
within 3 h postsurgery; slices were placed in culture
within the next 60–90min. Each day, 80% of the
medium (F-12; Thermo Fisher, Waltham, MA, USA)
was replenished with fresh medium. Selumetinib (sel)
(AZD624; Selleckchem, Munich, Germany), dactolisib
(dact) (NVP-BEZ235; Selleckchem) and saracatinib
(sar) (LC Laboratories, Woburn, MA, USA) were stored
at –80 ∘C in dimethyl sulphoxide (DMSO), and diluted
with serum-free culture medium to 0.5 μM, 0.5 or 1 μM,
or 1 μM, respectively. Slices were fixed and processed at
set time points. Relative changes in marker expression
or dead cells were determined by comparing neighbour-
ing DMSO-treated or drug-treated cultured slices with
neighbouring uncultured (0 h) slices. More details on
culture conditions and methods are provided in supple-
mentary material, Supplementary methods Table S1.
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IHC and biomarker analysis
Standard IHC analysis was performedwith dewaxed and
rehydrated paraffin sections as described previously [4],
with rabbit primary antibodies (supplementary material,
Supplementary methods Table S2) and BrightVi-
sion poly-horseradish peroxidase goat anti-rabbit and
3,3′-diaminobenzidine for detection (Immunologic,
Duiven, The Netherlands). Dehydrated stained sections
were counterstained with haematoxylin. Whole slide
image scans (Pannoramic 250 scanner; 3DHISTECH)
were used to quantify marker expression area (%;
cytoplasmic, nuclear, or membranous) in manually
selected regions of interest, by use of the Definiens
Tissue Studio software (Definiens, Munich, Germany).
For quantitative IHC analysis of marker expression
areas in uncultured tissue slices, Adobe Photoshop CS6
(Adobe Systems, San Jose, CA, USA) was used to draw
masks, and MATLAB (MathWorks, Natick, MA, USA)
was used to define viable tumour areas.
Quantification of necrosis and IHC results
H&E-stained sections of tumour slices were
pre-analysed by a pathologist prior to masks being
drawn on necrotic tumour areas with Adobe Photoshop
CS6, as described previously [4]. Relative decreases
in viability were calculated as follows: (1 – viability
in drug-treated/viability in DMSO control)× 100%.
Quantification of the phosphoprotein expression areas
was performed with Photoshop CS6, by drawing masks
on the stained areas; drawn masks were overlapped, and
the overlapping area was recoloured in green with the
magic wand tool in Photoshop CS6; the resulting differ-
entially coloured areas of single and overlapping stains
were measured with MATLAB or with Photoshop’s
histogram tool, and normalised to the total tumour area.
Statistical analysis
Data visualisation and statistical analyses were per-
formed with RStudio (RStudio, Boston, MA, USA) or
GraphPad Prism6 (GraphPad Software, San Diego, CA,
USA). For statistical comparisons, one-way ANOVA,
two-tailed paired Student’s t-test or unpaired Student’s
t-test was used. P values of <0.05 were considered to
be significant. Data are presented as mean± standard
deviation.
Results
Kras-driven NSCLC models show heterogeneity
in the histopathology of lesions
We recently demonstrated that, in KL-driven NSCLC,
the spectra of induced histopathologies depend on the
cell of origin [22]. To study phenotypic variability and
its dependence on genotype, in the current study we
used both KL and KP models, which were infected
with two progenitor cell type-restricted adenoviruses.
End-stage lung tumours were analysed with immuno-
histochemistry and digital pathology tools. In line with
our previous study [22], Ad5-CC10-Cre-infected KL
mice predominantly developed large ASC lesions with
an inner core of NKX2.1+/– (also known as TTF-1)
AC surrounded by a squamous p63+ region, as well
as occasional p63+/– NKX2.1+ mucinous or acinar
ACs lesions, whereas Ad5-SPC-Cre-infected KL mice
predominantly developed papillary NKX2.1+ AC
(Figure 1A). In KP mice, we observed the formation of
p63– NKX2.1+ ACs in a manner independent of the
progenitor cell (Figure 1A), consistent with a previous
report [19]. Subsequently, we considered AC lesions
of various histopathology subtypes as one group per
genotype, and compared these two groups (KL AC
and KP AC) with the ASCs formed in Ad5-CC10-Cre
infected mice (KL ASC), subdividing the latter into
their SCC and AC compartments.
We first assessed proliferation by quantifying IHC
images for Ki67, and found that proliferation dif-
fered strongly across our four groups (ANOVA F-test,
p< 0.0001; Figure 1B), with the SCC component of KL
ASC lesions showing particularly high proliferation.
We also noticed residual within-group variation in
proliferation, particularly in KP ACs (Figure 1B). Fur-
thermore, ASC tumours often contained necrotic islets,
which constitute a known clinical feature of ASC and
SCC (Figure 1A). Thus, KP and KL models, despite
being oncogenetically homogeneous, give rise to a
spectrum of NSCLCs with varying histopathological
and proliferation features.
Histopathology-specific variation in signalling
pathway activities in NSCLCs
We next compared oncogenic signalling activities
(supplementary material, Figure S1A) in the four
groups (KP AC, KL AC, KL SCC of ASC, and
KL AC of ASC) by staining for phosphorylated
extracellular signal-regulated kinase (pERK) 1/2
[mitogen-activated protein kinase (MAPK) pathway],
pAKT(S473) and p4EBP1 [phosphoinositide 3-kinase
(PI3K)–mammalian target of rapamycin (mTOR)
pathway], and pSRC(Y416) and phosphorylated
AMP-activated protein kinase (pAMPK) [liver kinase
B1 (LKB1)–mTOR pathway]. Marked differences
were detected both between and within lesion groups
(Figure 2A,B): the SCC regions of KL ASCs showed
increased expression of pSRC as compared with ACs,
and ASCs showed exclusive expression of pAKT; in
contrast, pERK expression was stronger in AC-histotype
tumours. Consistent with LKB1-dependent phospho-
rylation of the energy-sensing kinase AMPK, pAMPK
expression was decreased in KL tumours, as reported
previously [24]. Phosphorylation of the translational
repressor 4EBP1, indicating activation of the mTOR
complex 1 (mTORC1) biomass-regulating pathway,
showed high intertumour heterogeneity across groups.
Next, we investigated how representative signalling
in murine NSCLCs is of clinical tumours. We therefore
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018
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Figure 1. Histopathology-related heterogeneity of KL and KP NSCLC tumours. (A) IHC images depict p63 and NKX2.1 in KL and KP tumours.
The solid line indicates mucinous AC, the dotted lines (blue) indicate the ASCs and the AC cores of ASCs (black) or typical necrotic areas in
ASC [33]. Scale bars: 2mm (low-magnification images) and 100 μm (high-magnification images). (B) Quantification and representative IHC
images depicting Ki67 (stained area as percentage of whole tumour area) in KL and KP tumours (four to six analysed mice per tumour group;
each dot represents one tumour). Scale bar: 100 μm. One-way ANOVA (average per mouse was used as an experimental unit). p< 0.0001.
Data are shown as mean± standard deviation.
performed IHC analysis of a TMA encompassing human
SCCs (28), ASCs (13) and papillary ACs (25) for pAKT
and pERK (supplementary material, Figure S1B and
Table S3). Tumour samples (n= 10) for which replicate
punches from different subregions were included in
the TMA showed variable pAKT or pERK expression,
indicating spatial signalling heterogeneity in larger
tumours. We also determined the LKB1 and TP53
status, following previously validated IHC analysis
[13,20,22]; whereas most tumours showed varying but
positive nuclear TP53 protein accumulation, suggest-
ing TP53 pathway mutation, LKB1 expression varied
across NSCLC pathologies. Consistent with murine
findings, absence of LKB1 expression was found in all
three types of NSCLC pathology. In line with murine
NSCLC, human AC tumours expressed pAKT rarely
(one of 25 tumours), and significantly less often than
ASC tumours (5/13; Fisher’s test comparison with AC
tumours, p= 0.012) and SCC tumours (8/28; Fisher’s
test comparison with AC tumours, p= 0.026). pERK
expression was also examined; here, the majority of AC
tumours (20/25) and ASC tumours (9/13) were positive
for pERK, but significantly fewer SCC tumours were
positive for pERK (13/28; Fisher’s test comparison with
AC tumours, p= 0.02) (supplementary material, Figure
S1B and Table S3). Thus, both murine and human
NSCLCs showed marked differences in signalling
profiles, with an important part, but far from all, of this
intertumour variability being explained by histotype:
SRC, and even more so PI3K–AKT pathway activity,
is more frequently detected in ASC histotype tumours,
particularly in the SCC regions, whereas MAPK activity
is more frequently detected in AC histotype tumours.
Culture-induced alterations in DNA damage,
proliferation, and oncogenic signalling
Diagnostically informative disease models should
reflect the between-tumour and within-tumour sig-
nalling heterogeneity. Before describing our drug
perturbation experiments, we first discuss our tests per-
formed to analyse to what extent cultured precision-cut
tumour slices maintain the proliferative and signalling
features of the in situ tumour. This builds on our previ-
ous work [4], which showed (for KL ASC slices) that
rotating incubation units achieve optimal tissue viability
through intermittent medium immersion and oxygen
exposure (supplementary material, Figure S2A).
In samples cultured for 72 h, we found that the
medium-exposed section of each slice, in particular,
maintained viability (supplementary material, Figure
S2B); KL AC slices often showed a culture-induced
reduction in viability (supplementary material, Figure
S2C). Epithelial integrity was maintained, as shown
by sustained E-cadherin expression (supplementary
material, Figure S2D). Next, we compared func-
tional biomarkers in slices analysed at culture onset
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018
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Figure 2. Oncogenic signalling pathway phosphoproteins show heterogeneous spatial distribution in KL and KP NSCLCs. (A) Quantified
expression (percentage of tumour area stained) of pSRC(Y416), pAKT(S473), pERK1/2, pAMPK and p4EBP1 in Ad5-CC10-Cre-induced KL
SCC or AC of ASC tumour regions and Ad5-SPC-Cre-induced KL or KP AC tumours. Each dot represents a tumour (11–29 tumours from
seven mice for KL ASC, and five mice each for KL and KP AC), and lines and whiskers indicate mean± standard deviation of the average
values of individual tumours per histotype group. Significance was assessed with t-tests (average per mouse was used as an experimental
unit): *p< 0.05, **p< 0.01, ***p< 0.001. (B) IHC images of stained tumours induced by Ad5-CC10-Cre (KL) or Ad5-SPC-Cre (KL and KP); one
image for each of the phosphoproteins and lesion groups is shown by a beeswarm plot in (A). For Ad5-CC10-Cre KL tumours, the solid line
indicates mucinous AC, and black and red dotted lines define outer SSCs and inner AC cores of ASCs, respectively. Scale bars: 1mm.
with those in directly neighbouring slices that had
been cultured. After 24 h of culture, an increase in
γH2AX-marked DNA damage was visible (supple-
mentary material, Figure S3A). Furthermore, whereas
Ki67 was representative of native tissue in 0-h slices
(supplementary material, Figure S3B), Ki67 showed
a gradual decrease in AC slices, whereas KL ASC
slices revealed histotype-specific alterations: SCC
regions already showed decreased proliferation at 24 h,
whereas AC regions showed increased epithelial cell
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018
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proliferation starting 48 h after culture onset (supple-
mentary material, Figure S3C). This suggests that the
inner AC core of ASC tumours is particularly sen-
sitive to slicing-induced damage, perhaps akin to a
wound-healing response.
Next, we compared signalling activities in a panel
of in vivo tumours (instantly fixed) to slices analysed
at 0 h (fixed 90–120min after mice had been killed).
No significant alterations in pAKT, pERK, p4EBP1 or
pSRC expression were detected in 0-h slices (supple-
mentary material, Figure S4A), or in slices cultured
for 8 h (supplementary material, Figure S4B), indicat-
ing that pathway activities at culture onset or follow-
ing short-term culture represent the native tumours.
However, alterations were measured in slices cultured
for 24–48 h: selective pAKT induction was detected
in a number of ASC samples at 24 h (supplemen-
tary material, Figure S5A), whereas this was never
seen in ACs (supplementary material, Figure S6A),
and pERK expression showed variable changes in both
directions (supplementary material, Figure S5A). The
latter is probably explained by different pERK expres-
sion in the compared neighbouring slices before cul-
ture, as pERK shows strong spatial heterogeneity at
small scales (supplementary material, Figure S4C). The
most prominent alterations, detected at 24 and 48 h
in all lesions, were mTORC1 hyperactivation as mea-
sured by p4EBP1 induction, and SRC hyperactivation
(supplementary material, Figures S5A and S6A). These
alterations were observed regardless of medium supple-
mentation with fetal bovine serum (used routinely) or
autologous serum, or the use of serum-free conditions
(used for drug perturbations) (supplementary material,
Figure S6B).
Finally, we investigated whether these dynamic
signalling changes were peculiar to murine NSCLC
slices. Assessment of PTEN loss-driven murine prostate
tumour slices similarly showed rapid pERK induction
following slice culture (supplementary material, Figure
S7A). Furthermore, slices from freshly resected clinical
tumours showed elevated p4EBP1 and sustained or
increased pERK expression in both NSCLC (supple-
mentary material, Figure S5B) and prostate tumours
(supplementary material, Figure S7B).
Overall, this shows that, whereas NSCLC slices main-
tain viability during 72 h of ex vivo culture, marked
biological changes can be seen at the 24-h time point.
Therefore, tumour slices appear to constitute a good ex
vivomodel for in situ biology only for the first day. Then,
however, the ability of slices to model the in situ spatial
heterogeneity still makes them a valuable complement to
cell lines, which are more stable but also unrealistically
uniform.
Combination therapy with MAPK and PI3K–mTOR
inhibitors elicits cytotoxic responses
We now return to the central question of how the
observed intertumour and intratumour heterogeneities
in signalling affect pharmacodynamics. In light of the
above findings, we restricted ourselves to immediate and
short-term treatments, again comparing adjacent slices,
now treating one with a drug and the other with vehi-
cle control. We chose three compounds with reported
efficacy in preclinical studies on Kras-driven NSCLC
[14,25], namely the dual PI3K and mTOR inhibitor
NVP-BEZ235 or dact, the MEK inhibitor AZD6244 or
sel, and the SRC inhibitor sar (Figure 3A). The MAPK,
PI3K–AKT and LKB1–AMPK pathways all regulate
mTORC1 signalling to control cell growth and survival
[26,27], and loss of LKB1 activates FAK–SRC sig-
nalling to regulate invasiveness [14] (Figure 3A). First,
close to minimally effective concentrations at which
compounds suppressed their targeted pathways were
identified, with suppressed p4EBP1 and pAKT (for
dact), pERK (for sel) and pSRC (for sar) following
1–2 h or 24 h of treatment as read-outs (supplementary
material, Figure S8). Pathway inhibition was commonly
already detected following 2 h of treatment, at which
point signalling in DMSO-treated control slices was still
similar to that in uncultured slices (supplementary mate-
rial, Figure S8B).
Next, pairs of neighbouring tumour slices were cul-
tured either with compound or with DMSO, and the
viable fractions (%) of the tumour area in the slices’ top
sections were quantified, in contrast to necrotic regions
(supplementary material, Figure S9). We compared
this with neighbouring uncultured (0 h) slices, in which
relevant phosphoprotein markers were quantified (as
percentage of tumour area). The raw data from all per-
turbation studies are shown in supplementary material,
Table S4. We found that 24 h of treatment with single
compounds did not elicit noticeable cytotoxic responses
in any of the tumour groups (Figure 3B; difference from
DMSO of <5% for all samples). Interestingly, only one
of the three combinations, namely dact + sel, elicited
any substantial response (Figure 3C; a difference from
DMSO of >5% was found for four of nine ASC
tumours, five of nine KL AC tumours, and two of six
KP AC tumours). This was not accompanied by overt
cytostatic responses, as no differences in Ki67 were
measured between drug-treated and DMSO-treated con-
trols (supplementary material, Figure S10A). Finally,
the addition of sar to target SRC signalling enriched
in ASCs did not enhance cytotoxicity, as responses to
treatment with dact + sel+ sar were similar to those to
treatment with only dact + sel (supplementary material,
Figure S10B). We conclude that NSCLC slices of both
KL and KP genotypes, and regardless of AC or ASC
pathology, show a lack of sensitivity to single pathway
inhibition, but show selective sensitivity to combination
treatment with MAPK and PI3K–mTOR inhibitors.
Spatial aspects of oncogenic signalling correlate
with response to combination therapy
We subsequently investigated whether responses fol-
lowing dact + sel treatment were determined by
lesion-specific targeted pathway activities. As no sig-
nificant differences in viability reduction were detected
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018
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Figure 3. KL and KP tumour slices show cytotoxic responses to combined targeting of the MAPK and PI3K–mTOR pathways. (A) Signalling
diagram depicting molecular compounds and their targets utilised in this study. (B) Responses following 24 h of treatment with single
compounds: 0.5 or 1 μM dact, 0.5 μM sel, or 1 μM sar. The viable tissue area (percentage of tumour area) in drug-treated slices is correlated
with the viable area in neighbouring DMSO-treated controls. The diagonal line corresponds to equal viability, and the grey area corresponds
to the region with <5% difference between treated and control slices. Representative H&E images of matching DMSO-treated and
drug-treated slices are shown; regions of cell death are pseudo-masked in pink, and viable areas in purple. Scale bar: 300 μm. Greek letters
(α, β, γ, δ) and arrows in the scatterplot indicate the tumours shown in the images. KL ASC samples represent data measured in larger SCC
histotype regions; no visible response was detected in core KL ACs of ASC regions. (C) Correlation of viable tissue area in drug-treated and
matching DMSO control slices (percentage of total tumour area) in KL and KP tumours following 24 h of combination treatment with dact
+ sar (0.5 or 1 μM+ 1 μM), sel+ sar (0.5 μM+ 1 μM), or dact + sel (0.5 or 1 μM+ 0.5 μM). Of these, only the dact + sel combination elicited
cytotoxicity, which was quantified for the four histotype groups. (D) Comparison of drug responses after 24 h of dact + sel treatment in the
four different histotype groups: decrease in viability (%) measured as the ratio of the viable area in the drug-treated slice and the matching
DMSO control. One-way ANOVA was used for statistical comparison.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
8 K Närhi et al
Figure 4. Oncogenic signalling activities at treatment onset correlate with dact + sel combination treatment responses. (A) Drug responses
following 24 h of dact + sel treatment in slices representing KL SCC of ASC, KL AC of ASC, KL AC and KP AC tumour tissue, plotted against
expression (percentage of tumour area) of p4EBP1 or pERK1/2, indicating targeted pathway activities in source tumours at treatment onset.
Viability following drug treatment is depicted as relative decrease in viability (%). Spearman coefficients (ρ) are indicated with significance:
*p< 0.05, ***p< 0.001. Greek letters (α, β, γ, δ) indicate tumour samples shown in (C). (B) Scatterplot depicting the correlation of pERK
(y-axis) and p4EBP1 (x-axis) at treatment onset in relation to the relative decrease in viability (%; balloon size) in dact + sel-treated
slices after 24 h. The four tumour groups are indicated by colours; α, β, γ, δ indicate the tumour samples shown in (C). (C) Selected
phosphoprotein expression and drug response data from slice experiments plotted in (A) and (B), indicated by Greek letters (α, β, γ, δ).
Shown are representative images of H&E-stained sections with masks for dead (pink) and viable (purple) tissue, and IHC stains of p4EBP1
and pERK in the corresponding 0-h slices. Scale bars: 500 μm (top row) and 300 μm (bottom row).
between histotype groups (Figure 3D), these groups
were pooled for the subsequent analyses, which cor-
related drug responses with MAPK and PI3K–mTOR
activities; pAKT was excluded, as it was absent in most
KL ACs of ASC regions and all pure ACs, implying that
it does not contribute to drug sensitivity (supplemen-
tary material, Table S4). We compared the areas (%)
of p4EBP1 and pERK expression in uncultured (0 h)
slices, indicating in situ signalling pathway activities,
with the response to 24 h of dact + sel treatment in
neighbouring slices (supplementary material, Table S4).
Increased p4EBP1 expression correlated most clearly
with drug response (p< 0.001), but pERK expres-
sion also showed a significant correlation (p< 0.05)
(Figure 4A). Dissection of targeted pathway activities
showed concomitantly increased expression of both
pERK and p4EBP1 specifically in samples with the
most significant responses (>20% relative decrease in
viability) (Figure 4B,C; α, β, δ), whereas more resistant
samples showed selective activation of either pERK or
p4EBP1 (Figure 4B,C; γ). Hence, our data suggest that
increased activities of mTORC1 and MAPK sensitise to
combined MAPK + PI3K–mTOR inhibition.
Finally, we wished to more conclusively address
whether responses were related to increased sensitiv-
ity of individual cells dually active for the targeted
pathways, and investigated how the spatial distribu-
tion of p4EBP1 and pERK expression determined drug
responses. We therefore quantified the area of over-
lap between these phosphoproteins at treatment onset,
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and correlated this with drug-induced cytotoxicity. This
revealed a significant correlation (p< 0.001) between
the spatial overlap (percentage total tumour area) of
pERK and p4EBP1 expression and dact + sel responses
(Figure 5A,B); samples in which the extent of sig-
nalling overlap was smaller (<15%) were more resis-
tant. Interestingly, whereas the majority of AC samples
with increased signalling overlap (>15%; six samples)
showed significant drug responses, KL SCCs of ASC
samples with similar signalling overlap showed lower
drug responses (>15%; four samples), tentatively sug-
gesting an SCC histotype-specific resistance mechanism
(Figure 5A). Consistent with the thesis that a spatial cor-
relation exists between combination drug response and
signalling, analysis of individual ASC samples showed
intratumour regional differences in responses: regions
with larger areas of mTORC1 and MAPK signalling
overlap showed increased cytotoxicity (Figure 5C), and
the AC cores of ASCs showed increased cytotoxic-
ity as compared with the outer SCC regions in the
same tumour (supplementary material, Figure S10C). In
conclusion, we observed pronounced intralesional spa-
tial heterogeneity in Kras-associated signalling activ-
ities, resulting in sensitivity to combined inhibition
of PI3K–mTOR and MAPK pathways, particularly in
samples and tumour subregions in which both targeted
pathways are active.
Discussion
It is increasingly recognised that both phenotypic
and genetic diversities govern tumour evolution [2].
Although pharmacological screens are feasible on
patient-derived cultures [28], these, as well as more
routinely applied diagnostic assays, disregard such
spatial heterogeneities. We present here our analysis
of mutant Kras-related signalling in NSCLCs. Unex-
pectedly, we found that, whereas genetic drivers define
histopathology spectra, most of the signalling variance
in both murine and human tumours is explained by
histopathology. Specifically, increased PI3K–AKT
and SRC activities were more frequently detected in
ASCs, whereas MAPK activity was more selective for
ACs. In addition, pronounced intertumour and intratu-
mour heterogeneity in MAPK and biomass-regulating
mTORC1 activities were observed, possibly being
explained by intratumour variation in mutant Kras copy
gains, which are known to affect MAPK activity and
glucose metabolism [29,30], or regional differences
in nutrient availabilities. Importantly, the finding that
signalling variation in NSCLC relates to histopathol-
ogy matches our identification of histotype-specific
immune microenvironments in KL-driven NSCLC [22],
and, together with reported differences in energetic
dependencies [31,32] and epigenetic signatures [33],
warrants consideration of histotype-specific phenotypes
in treatment decisions.
The establishment of a tumour’s histopathology is
the culmination of a complex interplay between genetic
drivers, the tumour cell of origin, somatic gene alter-
ations, and factors in the microenvironment. There-
fore, the finding that signalling appears to be spe-
cific to NSCLC histotypes across species is tantalizing.
Although analysis of a larger set of samples is required,
this indicates a causative role for signalling in the for-
mation of histopathology subtypes. We detected both
restrictive PI3K–AKT activity and increased SRC activ-
ity in ASC lesions. This extends the finding of prior
studies that ascribed altered PI3K–AKT and SRC sig-
nalling to Lkb1 loss in Kras-driven NSCLC [14,15], but
we relate this to an alteration in histotype spectra, par-
ticularly an increase in ASCs. Interestingly, mutations
in the PI3K pathway have been detected specifically
in the SCC, but not in the AC, components of clini-
cal ASCs [34]. This implies that PI3K–AKT signalling
could indeed drive human squamous tumours, and cor-
roborates findings demonstrating SCC induction follow-
ing loss of the PTEN negative regulator of PI3K–AKT
signalling [35,36].
We used a slice explant model optimised for pul-
monary, breast and prostate cancer tissues [4] to investi-
gate how signalling heterogeneity in individual lesions
influences drug responses. NSCLC slices cultured on
rotating incubation units, to ensure continuous oxygena-
tion, were fragile and showed dynamic culture-induced
changes, most prominently altered proliferation and
mTORC1 hyperactivation. Although previous reports
showed sustained viability of clinical tumour slices
for 4–14 days [6,7,9,10], these studies derived con-
clusions from the selective analysis of cultured slices,
whereas we systematically compared neighbouring cul-
tured and uncultured slices. Furthermore, our study is
the first to deeply analyse intratumour oncogenic sig-
nalling, and shows that signalling and proliferation alter-
ations take place prior to overt changes in viability.
Culture in serum-free medium improved neither viabil-
ity nor signalling changes. Notably, increased activity
of mTORC1, an inducer of protein synthesis, was also
detected in clinical tumour slices. Thus, metabolic adap-
tation appears to be common to culture of primary tis-
sue, which corroborates reports showing that nutrient
dependencies ex vivo differ from those of native NSCLC
tumours [30,37].
We provide evidence that the ability of slices to,
at least temporarily, model in situ spatial heterogene-
ity makes them of unique diagnostic value. Specifi-
cally, responses to combined MAPK and PI3K–mTOR
inhibitor treatment closely correlated with the spatial
activities of both targeted pathways. Further affirming
the value of slices, our results on ex vivo inhibition of
KRAS effector pathways align with published preclini-
cal data; the finding that AC slices show selective sen-
sitivity to dact + sel combination treatment agrees with
the observation that combined MAPK + PI3K–mTOR
inhibition reduces the AC tumour burden of KrasG12D
mice more effectively than single pathway inhibition
[25]. Furthermore, KL mice with mixed ASC and SCC
spectrum tumours were shown to be largely unrespon-
sive to dact + sel treatment [14]. This is consistent with
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Figure 5. Combination treatment response is determined by spatial distribution of the targeted pathway activities in tumour slices. (A)
Correlation of dact + sel treatment with the areas of p4EBP1 and pERK overlap (%) in neighbouring 0-h slices in the four different tumour
groups. Drug response depicted as relative decrease in viability (%) is measured as the ratio of quantified viable area in drug-treated
and corresponding DMSO-treated controls. Spearman coefficients (ρ) are indicated with significance: *p< 0.05. (B) IHC images depicting
p4EBP1 expression (blue), pERK expression (red) or their overlapping expression (green) at 0 h in three KP or KL AC tumours selected from
the data plotted in (A) and (B). H&E images of drug-treated and matching DMSO-treated controls are pseudo-marked to indicate dead
(pink) and viable (purple) areas. Scale bars: 1mm (immunohistochemistry) and 200 μm (H&E). (C) H&E images of DMSO-treated or dact +
sel-treated slices showing dead (pink) and viable (purple) areas of a KL SCC of an ASC tumour selected from the data plotted in (A) and (B).
IHC images depicting p4EBP expression (blue), pERK expression (red) or their overlapping expression (green) at treatment onset. The yellow
dotted line outlines an area with low cytotoxicity (H&E image), lower pERK expression (IHC image) and lower phosphoprotein overlap than
in the area marked by the orange dotted line. Scale bars: 500 μm.
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low MAPK activity in ASC tumours, and resistance
of, particularly, the larger SCC regions to combination
treatment in slice explants. Interestingly, despite acti-
vation of SRC signalling in ASC tumours, inclusion of
sar did not exacerbate cytotoxicity in ASC slices, which
deviates from the regression of KL-driven tumours fol-
lowing dact + sel treatment in combination with the
non-selective SRC inhibitor dasatinib [14]. This discrep-
ancy is probably explained by the role of SRC activity
in invasion [38], and possibly also a role of antitumour
T-cell responses in dasatinib’s efficacy [39], as these
demand in vivomodelling. Together, our data support the
further development of slices to assess lesion-specific
oncogenic pathway dependencies, and suggest that their
use may complement preclinical studies on heteroge-
neous solid tumours.
Although all studied GEMM tumours are driven by
oncogenic Kras, strikingly, signalling activities, includ-
ing that of MAPK, are highly variable from tumour
to tumour. Taken together with, first, our finding that
overlapping signalling activities dictate combination
response, and second, the detection of similar sig-
nalling variabilities in clinical NSCLCs, this suggests
that spatially defined phenotypic heterogeneity may
also influence treatment efficacy in clinical samples.
Deeper dissection of signalling heterogeneity in the
context of clinical NSCLC is particularly relevant for
KL-driven tumours: no targeted inhibitors are known
for this disease subtype, and LKB1-mutant NSCLCs
have been shown to have an ‘immune-inert’ state of low
programmed death-ligand 1 (PD-L1) checkpoint protein
[13,39,40], making them unsuitable for immunother-
apy. Therefore, future efforts should investigate how
short-term slice cultures derived from patient tumours
can be used to study the impact of tumour-intrinsic
phenotypic variation on drug responses to clinically
prescribed therapies, or to compounds inhibiting novel
targets, or to validate the efficacy of combination strate-
gies. Overall, our study suggests that analysis of the
spatial activities of oncogenic functions, such as sig-
nalling activities, provides important diagnostic value
and should be used in addition to routinely applied
molecular and immunotherapy biomarkers.
In conclusion, we show that both the cell of origin
and genetic drivers play important roles in establish-
ing heterogeneous activities of commonly targeted
oncogenic signalling pathways, implying the existence
of NSCLC histopathology-specific signalling net-
works. Our findings caution against an over-reliance on
genetic biomarkers in diagnostic settings, particularly
if mutation-targeted therapies are lacking. Furthermore,
our study underscores a need for, and informs on, diag-
nostic assays to assess spatial signalling heterogeneity
when making personalised therapeutic decisions.
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